Casdin Capital buys $9,640,800 stake in Foundation Medicine Inc (FMI)

Foundation Medicine Inc (FMI) : Casdin Capital scooped up 55,000 additional shares in Foundation Medicine Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 390,000 shares of Foundation Medicine Inc which is valued at $9,640,800.Foundation Medicine Inc makes up approximately 8.45% of Casdin Capital’s portfolio.

Other Hedge Funds, Including , Price T Rowe Associates Inc Md reduced its stake in FMI by selling 18 shares or 0.03% in the most recent quarter. The Hedge Fund company now holds 54,952 shares of FMI which is valued at $1,358,413.Group One Trading boosted its stake in FMI in the latest quarter, The investment management firm added 20,661 additional shares and now holds a total of 304,651 shares of Foundation Medicine Inc which is valued at $7,530,973. Foundation Medicine Inc makes up approx 0.65% of Group One Trading’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in FMI in the latest quarter, The investment management firm added 11,675 additional shares and now holds a total of 317,874 shares of Foundation Medicine Inc which is valued at $7,857,845.California State Teachers Retirement System boosted its stake in FMI in the latest quarter, The investment management firm added 3,016 additional shares and now holds a total of 28,221 shares of Foundation Medicine Inc which is valued at $682,384.Gilder Gagnon Howe Co boosted its stake in FMI in the latest quarter, The investment management firm added 13,515 additional shares and now holds a total of 2,014,913 shares of Foundation Medicine Inc which is valued at $48,720,596. Foundation Medicine Inc makes up approx 0.90% of Gilder Gagnon Howe Co’s portfolio.

Foundation Medicine Inc opened for trading at $20.48 and hit $20.76 on the upside on Thursday, eventually ending the session at $20.63, with a gain of 0.54% or 0.11 points. The heightened volatility saw the trading volume jump to 93,169 shares. Company has a market cap of $721 M.

On the company’s financial health, Foundation Medicine Inc reported $-0.84 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.79. The company had revenue of $28.24 million for the quarter, compared to analysts expectations of $26.72 million. The company’s revenue was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.98 EPS.

Foundation Medicine Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies including leukemia lymphoma myeloma and various sarcomas and pediatric cancers are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *